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Abstract 
Accumulating evidence suggests that antipsychotics affect dopamine release 
from dopaminergic neurons, but the precise mechanisms are not fully understood. 
Besides, there are few studies on the effects of antipsychoti cs on intracellular 
dopamine content. In this study, the effects of 8 antipsychotics on dopamine release 
and intracellular dopamine content in PC12 cells were investigated. Pretreatment with 
haloperidol, spiperone, pimozide, aripiprazole and risperidone markedly inhibited high 
potassium-evoked dopamine release. By contrast,  pretreatment with chlorpromazine 
slightly increased high potassium-evoked dopamine release, while pretreatment with 
sulpiride and olanzapine had no effect. Haloperidol, spiperone, pimozide, 
chlorpromazine, aripiprazole and olanzapine evoked dopamine release, while sulpiride 
and risperidone had no effect. In addition, haloperidol, spiperone, pimozide, 
aripiprazole and risperidone reduced intracellular dopamine content in a 
concentration-dependent manner. These results suggest that the reduction in high 
potassium-evoked dopamine release by pretreatment with antipsychotics results from 
the reduction in vesicular dopamine content. Treatment with the 8 antipsychotics did 
not affect the expression of total or phosphorylated tyrosine hydroxylase. Instead, 
haloperidol, spiperone, pimozide and aripiprazole as well as reserpine transiently 
increased extracellular levels of dopamine metabolites.  In addition, haloperidol, 
spiperone, pimozide, aripiprazole and risperidone reduced vesicular [
3
H]dopamine 
transport. These results suggest that the inhibition of vesicular dopamine transport by 








Recent studies using positron emission tomography (PET) or single photon 
emission computed tomography (SPECT) have clarified the pathophysiologic changes 
in presynaptic regions of dopaminergic neurons in schizophrenia. Higher [
123
I]IBZM 
binding to dopamine D2 receptors during depletion of endogenous dopamine  in patients 
with schizophrenia than in healthy controls has suggested that occupancy of dopamine 
D2 receptors by dopamine is increased (Abi-Dargham et al., 2000). In addition, 




C]DOPA and high displacement of 
[
123
I]IBZM in response to amphetamine in patients with schizophrenia have suggested 
that presynaptic dopamine levels are increased (Abi-Dargham et al., 1998; Lindström et 
al, 1999; McGowan et al., 2004). These recent findings have indicated that presynaptic 
dopaminergic neurons themselves as well as postsynaptic dopamine receptors  are 
important for an understanding of the pathophysiology of schizophrenia. 
It has been reported that antipsychotics affected dopamine release, although 
their clinical efficacy may be attributed to the blocking of postsynaptic dopamine 
receptors. Haloperidol, spiperone and clozapine increased dopamine release in rat 
striatum in vitro  or in vivo  (Seeman and Lee, 1975; Dismukes and Mulder, 1977 ; Drew 
et al., 1990). These antipsychotics also inhibited the electrically-stimulated dopamine 
release from rat striatal slices (Seeman and Lee, 1975; Dismukes and Mulder, 1977) 
and it was suggested that the effect of haloperidol was not related to the interaction 
with dopamine D2 receptors (Dismukes and Mulder, 1977). However, it has been 
reported that haloperidol and other antipsychotics increased the electrically-stimulated 
dopamine release by blocking dopamine autoreceptors in rat striatal slices (Farnebo 
and Hamberger, 1971; Dwoskin and Zahniser, 1986). Therefore, the effects of 
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antipsychotics on dopamine release are a matter of debate.  
Since presynaptic dopamine levels are suggested to be increased in 
schizophrenia as described above, it is important to analyze the effects of 
antipsychotics on intracellular dopamine content as well as dopamine release. However, 
there are few studies on the effects of antipsychotics on intracellular dopamine content. 
Thus, in this study, we investigated intracellular dopamine content in rat adrenal 
pheochromocytoma PC12 cells and rat mesencephalic cultures after treatment with 
antipsychotics. PC12 cells express vesicular monoamine transporter (VMAT) 1, while 
dopaminergic neurons express VMAT 2 (Schuldiner, 1994). In spite of the difference, 
PC12 cells share many features of dopaminergic neurons relating to the synthesis, 
storage, release and metabolism of dopamine (Greene and Rein, 1977; Tuler et al., 
1989). Therefore, we used PC12 cells as a dopaminergic neuronal model. We also used 
rat mesencephalic cultures because the cultures are known to contain dopaminergic 
neurons. Generally, antipsychotics are divided in two basic classes; typical and 
atypical. In this study, we used typical (haloperidol, spiperone, pimozide, 
chlorpromazine and sulpiride) and atypical (aripiprazole, risperidone and olanzapine) 
antipsychotics. All the antipsychotics have antagonistic activity for dopamine D2 
receptors, although aripiprazole is a dopamine D2 receptor partial agonist and acts as 
an agonist on presynaptic autoreceptors  (Kikuchi et al., 1995). Our findings revealed 
that haloperidol, spiperone, pimozide and aripiprazole reduced  intracellular dopamine 
content and inhibited vesicular dopamine transport.
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2. Materials and Methods 
2.1. Reagents 
Haloperidol, spiperone, pimozide, racemic sulpiride, risperidone, reserpine, 
adenosine 5’-triphosphate magnesium salt, digitonin and ascorbic acid were purchased 
from Sigma (St. Louis, MO). Chlorpromazine hydrochloride and pargyline 
hydrochloride were obtained from Nacalai Tesque (Kyoto, Japan). Olanzapine was 
purchased from Toronto Research Chemicals (Toronto, Canada). [7, 8-
3
H]dopamine 
was obtained from GE Healthcare (Buckinghamshire, UK). Aripiprazole was kindly 
provided by Otsuka Pharmaceutical Company (Tokyo, Japan). 
 
2.2. Cell cultures 
 PC12 cells, obtained from American Type Culture Collection ( Manassas, VA), 
were cultured on tissue-culture treated 100-mm cell culture
 
dishes (Cat# 353003, BD 
Falcon, Franklin Lakes, NJ) in Dulbecco’s modified Eagle’s medium supplemented 
with 5% fetal calf serum and 10% horse serum as described previously (Kumar et al., 
2003). Cell cultures were incubated at  37°C in a humidified atmosphere of 95% air and 
5% CO2. 
Rat mesencephalic cultures were established according to methods described 
previously (Izumi Y et al., 2009). Briefly, the ventral two -thirds of the mesencephalon 
were dissected from rat embryos on the 16th day of gestation. The tissues were then 
chemically and mechanically dissociated into single cell suspensions. Cells were plated 





. Cultures were maintained in Eagle’s minimum essential medium (EMEM) 
containing 10% fetal calf serum [1-4 days in vitro  (DIV)] or horse serum [5-9 DIV]. We 
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changed fetal calf serum into horse serum during the latter term of cultivation in order 
to inhibit excessive glial proliferation. Cultures were also incubated at 37°C in a 
humidified atmosphere of 95% air and 5% CO 2. The animals were treated in accordance 
with the guidelines of the Kyoto University animal experimentation committee and of 
the Japanese Pharmacological Society.  
 
2.3. Measurement of intracellular dopamine content 
Intracellular dopamine content was measured by high performance liquid 
chromatography with electrochemical detection (HPLC-ED) as described previously 
(Izumi et al., 2008). PC12 cells were seeded into 35-mm cell culture dishes (BD 




 and grown for 24 h, then exposed to drugs. 
Mesencephalic cultures were exposed to drugs at 8 DIV. To measure intracellular 
dopamine content after treatment with drugs for 24 h, cells were scraped, centrifuged 
and resuspended in extraction buffer (200 L) (0.1 N perchloric acid containing 10 mM 
sodium disulfite and 1 mM EDTA). After sonication, lysates were centrifuged at 17 ,000 
g for 30 min. The supernatants (2 L) were analyzed by HPLC-ED. The detection limit 
in our system was 10 fmol dopamine. In this experiment, more than 100 fmol dopamine 
was used for analysis. Intracellular dopamine content in sham-treated cells was 
expressed as 100%. The HPLC system consisted of  an automatic sample injector 
(Model 231, Gilson, Villiers-le-Bel, France), a pump (EP-300, Eicom, Kyoto, Japan), a 
degasser (DG-300, Eicom), a reverse-phase column (Eicompak CA-5ODS, inside 
diameter: 2.1 mm, length: 150 mm, Eicom), a column oven (ATC-300, Eicom) and an 
electrochemical detector (ECD-300, Eicom) with a working electrode versus an 
Ag/AgCl reference electrode. The working electrode was maintained at an oxidative 
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potential of +750 mV. The mobile phase consisted of 0.1 M acetate-citrate buffer (pH 
3.7) containing 300 mg/L sodium octylsulfate, 5 mg/L EDTA-2Na and 16% methanol, 
and the flow rate was set at 0.23 mL/min. 
 
2.4. Measurement of extracellular dopamine, 3, 4-dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA) levels 
To measure extracellular DOPAC and HVA levels after treatment with drugs 





 and grown for 24 h, then exposed to drugs. After treatment  with drugs for 24 
h, the conditioned medium was added to one-tenth volume of extraction buffer (×10) 
and centrifuged. The supernatants (2 L) were analyzed by HPLC-ED. To measure 
extracellular dopamine, DOPAC and HVA levels after treatment with drugs for 1 h, 





 and grown for 24 h, then exposed to drugs. Cells were treated with 
drugs in Krebs-Ringer-HEPES buffer (125 mM NaCl, 4.8 mM KCl, 25 mM HEPES, 1.2 
mM MgSO4, 1.2 mM KH2PO4, 5.6 mM glucose and 2.2 mM CaCl2, pH 7.4) for 1 h. 
Supernatants were added to one-tenth volume of extraction buffer (×10) and 
centrifuged. The supernatants (20 L) were analyzed by HPLC-ED. 
 
2.5. Measurement of dopamine release in the presence of pargyline and ascorbic acid  





 and grown for 24 h. Cells were treated with drugs for 30 min or 1 h in 
Krebs-Ringer-HEPES buffer containing 10 M pargyline and 1 mM ascorbic acid. 
Pargyline and ascorbic acid were added in order to inhibit dopamine metabolism and to 
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prevent dopamine oxidation, respectively. Supernatants were added to one-tenth 
volume of extraction buffer (×10) and centrifuged. The supernatants (20-30 L) were 
analyzed by HPLC-ED.  
 
2.6. Western blotting 





 and grown for 24 h, then exposed to drugs. After treatment with drugs for 24 
h, cells were washed twice with cold Tris -buffered saline, harvested and lysed in buffer 
(200 L) containing 20 mM Tris (pH 7.0), 25 mM -glycerophosphate, 2 mM EGTA, 
1% Triton-X-100, 1 mM phenylmethylsulfonyl fluoride, 1% aprotinin, 2 mM 
dithiothreitol and 1 mM vanadate on ice. The lysates were centrifuged at 17,000 g for 
30 min at 4°C. The protein concentrations of the supernatant were normalized and 
mixed in equal amounts with sample buffer composed of 124 mM Tris (pH 6.8), 4% 
sodium dodecyl sulfate, 10% glycerol, 0.02% bromophenol blue and 4% 
2-mercaptoethanol. After denaturation by boiling at 100 °C for 5 min, samples (10 g of 
protein) were loaded onto a sodium dodecyl sulfate -polyacrylamide gel, separated 
electrophoretically and transferred to a polyvinylidene fluoride membrane (Millipore, 
Billerica, MA). The membrane was incubated for 1 h with 10 mM Tris -buffered saline 
(pH 7.6) containing 0.1% Tween 20 and 5% skim milk to block non-specific binding. 
Subsequently, the membrane was probed with anti -tyrosine hydroxylase (TH; 
Chemicon/Millipore, Temecula, CA), anti-phospho-Ser19 TH, anti-phospho-Ser31 TH 
and anti-phospho-Ser40 TH (Phosphosolutions, Aurora, CO) or 
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Ambion, Austin, TX) for 1 
h and with horseradish peroxidase-conjugated secondary antibody (GE Healthcare) for 
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1 h. The membrane-bound secondary antibody was detec ted with an enhanced 
chemiluminescence detection system (ECL or ECL-Plus, GE Healthcare). 
 
2.7. Measurement of vesicular [
3




H]dopamine transport was determined as described previously 
(Höltje et al., 2000) with a slight modification (Izumi et al., 2008). After removing 
medium, cells from a confluent 100-mm dish were washed twice with 10 mM 
phosphate-buffered saline (pH 7.5) and harvested with potassium glutamate buffer (KG 
buffer; 150 mM potassium glutamate, 20 mM HEPES, 4 mM EGTA, 1 mM MgCl2, 10 
M pargyline and 1 mM ascorbic acid, adjusted to pH 7.0 with KOH). Pargyline and 
ascorbic acid were added in order to inhibit dopamine metabolism and to prevent 
dopamine oxidation, respectively. The cell suspension was centrifuged and resuspended 
in KG buffer supplemented with 10 M digitonin and incubated for 5 min at 37°C to 
selectively permeabilize the plasma membrane. Permeabilized cells were distributed 
into 30 tubes and washed by adding ice-cold KG buffer (500 L) and spun down at 
1,000 g for 2 min at 4°C. Uptake was started by adding KG buffer (100 L) containing 
5 mM Mg-ATP and 50 nM [
3
H]dopamine. Drugs to be tested were applied during this 
step. Incubation was performed for 30 min at 37°C and stopped by adding ice-cold KG 
buffer (700 L), followed by a rapid centrifugation. After rinsing with KG buffer, the 
cell pellet was lysed in 0.4% Triton  X-100 to measure radioactivity by scintillation 
counting. A non-specific value was determined using reserpine (10 M) and subtracted 




The statistical significance of the difference among three or more groups of 
individual data was analyzed by the one-way analysis of variance (ANOVA) and post 
hoc multiple comparison using Tukey’s test. The statistical significance of the 
difference between two groups of individual data was analyzed by unpaired t test. 




3.1. Effects of antipsychotics on dopamine release in the presence of pargyline and 
ascorbic acid and intracellular dopamine content in PC12 cells 
To investigate whether antipsychotics affect exocytotic dopamine release, the 
amount of extracellular dopamine released by high potassium was determined by 
HPLC-ED. In this experiment, we used pargyline and ascorbic acid to inhibit dopamine 
metabolism and to prevent dopamine oxidation, respectively. Treatment with pargyline 
and ascorbic acid for 1 h almost completely inhibited dopamine metabolism and 
retained extracellular dopamine (Fig. 1A-C). High potassium is known to induce 
depolarization and then evoke a calcium-dependent release of dopamine. We confirmed 
that the high potassium-evoked release did not occur in calcium-free buffer (sham, 100 
± 23.4%; KCl (60 mM), 119.3 ± 14.8%). After exposure to antipsychotics (1 M) for 24 
h, PC12 cells were stimulated with KCl (60 mM) for 30 min. Haloperidol, spiperone, 
pimozide, aripiprazole and risperidone markedly reduced high potassium-evoked 
dopamine release. Chlorpromazine slightly increased, but sulpiride and olanzapine did 
not affect high potassium-evoked dopamine release (Fig. 1D). To investigate whether 
antipsychotics affect spontaneous dopamine release , the amount of extracellular 
dopamine released by the treatment with antipsychotics (1 M) for 1 h was determined 
by HPLC-ED. Haloperidol, spiperone, pimozide, chlorpromazine, aripiprazole and 
olanzapine evoked dopamine release, whereas sulpiride and risperidone had no effect 
(Fig. 1E). Next, we examined the effects of antipsychotics on intracellular dopamine 
content in PC12 cells. Cells were exposed to drugs (1 M) for 24 h, and then 
intracellular dopamine content was measured by HPLC-ED. Haloperidol, spiperone, 
pimozide and aripiprazole markedly reduced intracellular dopamine content and 
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risperidone did so modestly. Chlorpromazine increased intracellular dopamine content 
slightly, while sulpiride and olanzapine had no effect  (Fig. 1F).  
To examine the concentration dependency of the effects of these drugs on 
intracellular dopamine content, PC12 cells were treated with various concentrations of 
drugs for 24 h. Haloperidol, spiperone, pimozide, aripiprazole and risperidone reduced 
intracellular dopamine content in a concentration-dependent manner, while 
chlorpromazine increased intracellular dopamine content in a bell-shaped 
concentration-dependent manner (Fig. 2). 
 
3.2. Effects of antipsychotics on intracellular dopamine content in primary 
mesencephalic dopaminergic neurons 
 To confirm the effect of antipsychotics on intracellular dopamine content, we 
used primary mesencephalic cultures, which contain dopaminergic neurons . After the 
exposure of mesencephalic cultures to drugs (1 M) for 24 h, intracellular dopamine 
content was measured by HPLC-ED. As shown in Fig. 3, haloperidol, spiperone, 
pimozide, aripiprazole and risperidone reduced intracellular dopamine content 
significantly, while chlorpromazine, sulpiride and olanzapine had no effect. The drugs 
which reduced intracellular dopamine content in PC12 cells were the same as those that 
did so in mesencephalic cultures.  
 
3.3. Effects of antipsychotics on the expression of tyrosine hydroxylase in PC12 cells 
Next, we examined the mechanisms behind the reduction in intracellular 
dopamine content. TH is a rate-limiting enzyme in dopamine synthesis and the 
phosphorylation of TH at serine (Ser) residues, Ser19, Ser31 and Ser40 , is known to 
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increase its activity (Dunkley et al., 2004). Total and phosphorylated TH protein levels 
were examined to investigate whether the reduction in intracellular dopamine content 
results from inhibition of dopamine synthesis.  Exposure to antipsychotics (1 M) for 
24 h did not affect total or phosphorylated TH protein levels (Fig. 4).  
 
3.4. Effects of antipsychotics on the extracellular DOPAC and HVA levels in PC12 cells 
It is known that dopamine is metabolized to DOPAC and HVA, which are 
mainly present extracellularly. To investigate whether the reduction in intracellular 
dopamine content results from the facilitation of dopamine metabolism, extracellular 
DOPAC and HVA levels in PC12 cells after exposure to antipsychotics (1 M) for 24 h 
were measured by HPLC-ED. Neither extracellular DOPAC nor extracellular HVA 
levels were changed (Fig. 5). 
We also measured extracellular dopamine, DOPAC and HVA levels in PC12 
cells after exposure to antipsychotics or reserpine (1 M) for 1 h by HPLC-ED. 
Haloperidol, spiperone, pimozide and aripiprazole as well as reserpine increased 
extracellular DOPAC and HVA levels, though pimozide and aripiprazole increased 
extracellular dopamine levels in addition to extracellular dopamine metabolites. 
Chlorpromazine markedly and olanzapine slightly increased only extracellular 
dopamine levels, while sulpiride and risperidone had no effect on extracellular levels 
of dopamine and dopamine metabolites (Fig. 6). 
 
3.5. Effects of antipsychotics  on vesicular [
3
H]dopamine transport in the presence of 
pargyline and ascorbic acid in PC12 cells. 
To investigate whether antipsychotics reduce intracellular dopamine content 
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via a reserpine-like effect, the effect of antipsychotics  on vesicular dopamine transport 
was examined. In this experiment, pargyline and ascorbic acid were added in order to 
inhibit dopamine metabolism and to prevent dopamine oxidation, respectively.  In 
digitonin-permeabilized cells, the amount of [
3
H]dopamine taken up into vesicles for 
30 min in the presence of antipsychotics (10 M) was measured. Haloperidol, 
spiperone, pimozide, aripiprazole  and risperidone inhibited the incorporation of 
[
3
H]dopamine into vesicles. On the other hand, chlorpromazine, sulpiride and 
olanzapine had no effect (Fig. 7). 
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4. Discussion 
In this study, we examined the effects of antipsychotics on dopamine release  in 
the presence of pargyline and ascorbic acid . Pretreatment with haloperidol, spiperone, 
pimozide, aripiprazole and risperidone reduced high potassium-evoked dopamine 
release. In addition, haloperidol, spiperone, pimozide, aripiprazole  and risperidone 
also reduced intracellular dopamine content in a concentration-dependent manner in 
PC12 cells. As high potassium-evoked dopamine release was attributed to 
calcium-dependent exocytosis, it is suggested that these antipsychotics may reduce 
vesicular dopamine content. Furthermore, we confirmed that the same drugs decreased 
intracellular dopamine content in mesencephalic cultures. Therefore, it is suggested 
that the effects of antipsychotics on intracellular dopamine content are not restricted to 
PC12 cells. Sulpiride and olanzapine had no effect on high potassium-evoked dopamine 
release or intracellular dopamine content. Chlorpromazine slightly increased the high 
potassium-evoked dopamine release and intracellular dopamine content in PC12 cells. 
However, the concentration at which chlorpromazine significantly increased 
intracellular dopamine content changed between 0.3 M and 1 M. The variation in the 
concentration might be brought about by a slight difference in the experimental 
conditions. 
We used antipsychotics at a concentration of 1 M, which was much higher 
than Ki values for dopamine D2 receptors (Burstein et al., 2005). Therefore, it was 
considered that all antipsychotics tested in this study sufficiently antagonize dopamine 
D2 receptors. However, chlorpromazine, sulpiride and olanzapine did not reduce 
intracellular dopamine content, while haloperidol, spiperone, pimozide, aripiprazole 
and risperidone reduced intracellular dopamine content in a concentration-dependent 
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manner. Furthermore, we have reported that dopamine receptor agonists as well as 
antagonists reduced intracellular dopamine content in PC12 cells (Izumi et al., 2008).  
Taken together, we considered that dopamine D2 receptors are not necessarily required 
for the reduction of intracellular dopamine content by antipsychotics. 
We investigated the mechanisms underlying the reduction of intracellular 
dopamine content by antipsychotics. The present results showed that antipsychotics 
had no effect on the expression of total TH or phosphorylated TH, indicating that the 
reduction is not brought about by the inhibition of dopamine synthesis. Inhibition of 
vesicular dopamine transport is thought to be another mechanism behind the reduction 
of intracellular dopamine content. It is known that r eserpine, an inhibitor of VMAT, 
causes the depletion of intracellular dopamine. Furthermore, it has been reported that 
reserpine increased catecholamine release (Mahata et al., 1996) and we confirmed that 
reserpine evoked dopamine release in our experiments (data not shown). Haloperidol, 
spiperone, pimozide and aripiprazole, which reduced intracellular dopamine content, as 
well as reserpine, increased dopamine release in the presence of pargyline and ascorbic 
acid. Risperidone reduced intracellular dopamine content, but did not significantly 
increase dopamine release. Since the reduction in intracellular dopamine content 
caused by risperidone was less than that caused by haloperidol, s piperone, pimozide or 
aripiprazole, the change in dopamine release caused by risperidone might be 
undetectable. In addition, reserpine increases extracellular DOPAC and HVA levels 
(Anden et al., 1964; Roffler-Tarlov et al., 1971) because cytosolic dopamine which is 
not incorporated into vesicles by reserpine is metabolized and transported 
extracellularly (Roffler-Tarlov et al., 1971). In the present study, treatment with 
haloperidol, spiperone, pimozide and aripiprazole as well as reserpine for 1 h increase d 
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extracellular DOPAC and HVA levels. Therefore, it is suggested that haloperidol, 
spiperone, pimozide and aripiprazole  have a reserpine-like effect. Although treatment 
with haloperidol, spiperone, pimozide or aripiprazole for 1 h increased extracellular 
DOPAC and HVA levels significantly, these antipsychotics did not change the total 
amount of extracellular DOPAC or HVA for 24 h. It is suggested that the transient 
change in 1 h was hidden because the increase in extracellular dopamine metabolites 
for 1 h was very low compared to the total amounts of metabolites released 
extracellularly for 24 h.  Treatment with pimozide, chlorpromazine, aripiprazole and 
olanzapine for 1 h increased extracellular dopamine levels in the presence or absence 
of pargyline and ascorbic acid. They might have additional mechanisms for dopamine 
release. 
Haloperidol, spiperone, pimozide and aripiprazole,  which reduced 
intracellular dopamine content and increased extracellular DOPAC and HVA levels, 
inhibited vesicular [
3
H]dopamine transport in the presence of pargyline and ascorbic 
acid. These results suggest that the cytosolic dopamine which is not incorporated into 
vesicles is metabolized, and then released extracellularly, leading to the reduction of 
intracellular dopamine content. Previously, it has been reported that  haloperidol had 
reserpine-like effects (Delanoy and Dunn, 1982) and that spiperone inhibited the 
transport of serotonin into membrane vesicles isolated from platelet dense granules 
(Dannies et al., 1984). Haloperidol inhibited vesicular transport and the formation of 
the pH gradient of synaptic vesicles, although haloperidol at concentrations that 
inhibited vesicular transport did not dissipate the pH gradient (Moriyama et al., 1993; 
Yasumoto et al., 2009). In addition, i t has been reported that pramipexole and 
ketanserin, an antagonist of serotonergic receptors, bound directly to VMAT (Darchen 
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et al., 1988; Izumi et al., 2008). Taking these reports into consideration, the inhibition 
of vesicular transport by antipsychotics may derive from a reduction of the vesicular 
pH gradient or from direct inhibition of transporter activity. As described in the 
Introduction, VMAT 1 is expressed in PC12 cells, while VMAT 2 is expressed in the 
brain (Schuldiner, 1994). Regardless of the difference in the isoforms, in our 
experiments, the reduction of intracellular dopamine content by antipsychotics was 
observed in both PC12 cells and mesencephalic cultures. These results suggest that the 
difference in VMAT isoforms does not influence the inhibition of vesicular transport by 
antipsychotics. Since VMAT is also responsible for the transport of serotonin, 
norepinephrine and epinephrine into vesicles , haloperidol, spiperone, pimozide and 
aripiprazole are likely to affect vesicular transport of the other monoamines as well as 
dopamine. In fact, a previous report demonstrated that spiperone inhibited the transport 
of serotonin into membrane vesicles (Dannies et al., 1984). 
As described above, presynaptic dopamine content is suggested to be increased 
in patients with schizophrenia  (Abi-Dargham et al., 1998; Lindström et al, 1999; 
McGowan et al., 2004). It is thought that the increase in presynaptic dopamine content  
mainly represents the increase in vesicular dopamine content because most of the 
intracellular dopamine in dopamine neurons is accumulated into synaptic vesicles 
(Lyon et al., 2009). However, since it is known that catecholamines leak from vesicles 
into cytosol (Floor et al., 1995; Eisenhofer et al., 2004), cytosolic dopamine may also 
be increased in schizophrenia. Excessive cytosolic dopamine could be harmful to 
dopaminergic neurons because dopamine was easily oxidized and produced reactive 
oxygen species and oxidized intermediates  (Stokes et al., 1999). These factors 
inactivated tyrosine hydroxylase, impaired the dopamine transporter and inhibited 
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mitochondrial NAD(P)H dehydrogenase (Ben-Shachar et al., 1995; Kuhn et al., 1999; 
Whitehead et al., 2001).  All the antipsychotics used in this study are effective against 
schizophrenia by inhibiting dopamine-mediated signal transduction in postsynaptic 
neurons. In addition, it is possible that haloperidol, spiperone, pimozide, aripiprazole 
and risperidone, which reduced intracellular dopamine content in the present study, 
suppress the dysfunction of dopaminergic neurons.  
In summary, haloperidol, spiperone, pimozide and aripiprazole reduced 
exocytotic dopamine release, intracellular dopamine content and vesicular dopamine 
transport. These findings suggest that the inhibition of vesicular transport by these 
antipsychotics induces the decrease in vesicular dopamine content. Further studies will 
be required to elucidate the mechanism underlying the inhibition of vesicular transport 
by these antipsychotics. 
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Figure legends 
Fig. 1 Effects of antipsychotics on dopamine release in the presence of pargyline and 
ascorbic acid and intracellular dopamine content in PC12 cells. A-C: Cells were 
incubated with Krebs-Ringer-HEPES buffer for 1 h in the presence of pargyline (10 
M) and ascorbic acid (1 mM). The extracellular dopamine (A), DOPAC (B) and HVA 
(C) levels were determined by HPLC-ED. Data shown are mean values ± S.E.M. (n=3) 
from a representative experiment. 
##
p < 0.01, 
###
p < 0.001, compared with control. D: 
Cells were pretreated with 8 kinds of drugs (1 M) for 24 h. After a washout, cells were 
treated with KCl (60 mM) for 30 min in the presence of pargyline (10 M) and ascorbic 
acid (1 mM) and then the extracellular dopamine levels were measured by HPLC-ED. 
Pargyline and ascorbic acid were added in order to inhibit dopamine metabolism and to 
prevent dopamine oxidation, respectively.  Data shown are mean values ± S.E.M. (n=3) 
from a representative experiment. 
###
p < 0.001, compared with KCl alone. E: Cells 
were treated with antipsychotics (1 M) for 1 h in the presence of pargyline (10 M) 
and ascorbic acid (1 mM). The extracellular dopamine levels were determined by 
HPLC-ED. Data shown are mean values ± S.E.M. (n=4) from a representative 
experiment. 
##
p < 0.01, 
###
p < 0.001, compared with sham. F: Cells were treated with 
antipsychotics (1 M) for 24 h and then the intracellular dopamine content was 
measured by HPLC-ED. Data shown are mean values ± S.E.M. (n=3) from a 
representative experiment. 
#
p < 0.05, 
###
p < 0.001, compared with sham. Each 
experiment was repeated three times.  
 
Fig. 2 Concentration-dependent effects of antipsychotics on intracellular dopamine 
content in PC12 cells. A-H: Cells were treated with various concentrations of drugs 
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(0.1-3 M) for 24 h and then the intracellular dopamine content was measured by 
HPLC-ED. Data shown are mean values ± S.E.M. (n=3) from a representative 
experiment. Each experiment was repeated three times. 
#
p < 0.05, 
##
p < 0.01, 
###
p < 
0.001, compared with sham. 
 
Fig. 3 Effects of antipsychotics on intracellular dopamine content in primary 
mesencephalic cultures. A: Cultures were treated with typical antipsychotics (1 M) 
for 24 h and then the intracellular dopamine content was measured by HPLC -ED. B: 
Cultures were treated with atypical antipsychotics (1 M) for 24 h and then the 
intracellular dopamine content was measured by HPLC -ED. Data shown are mean 
values ± S.E.M. (n=3) from a representative experiment. Each experiment was repeated 
three times. 
#
p < 0.05, 
##
p < 0.01, 
###
p < 0.001, compared with sham. 
 
Fig. 4 Effects of antipsychotics on total and phosphorylated  TH expression in PC12 
cells. Cells were treated with antipsychotics (1 M) for 24 h. Total TH (~60 kDa), 
phosphorylated TH (p-Ser19, p-Ser31 and p-Ser40 TH; ~60 kDa) and GAPDH (36 kDa) 
protein levels were analyzed by Western blotting with the respective antibody. The 
experiment was repeated three times.  
 
Fig. 5 Effects of treatment with antipsychotics for 24 h on extracellular DOPAC and 
HVA levels in PC12 cells. Cells were treated with antipsychotics (1 M) for 24 h. The 
extracellular DOPAC and HVA levels were measured by HPLC-ED. Data shown are 
mean values ± S.E.M. (n=3) from a representative experiment. Each experiment was 
repeated three times. 
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Fig. 6 Effects of treatment with antipsychotics for 1 h on extracellular dopamine, 
DOPAC and HVA levels in PC12 cells. Cells were treated with antipsychotics (1 M) or 
reserpine (1 M) for 1 h. The extracellular dopamine (A), DOPAC (B) and HVA (C) 
levels were measured by HPLC-ED. Data shown are mean values ± S.E.M. (n=4) from a 
representative experiment. Each experiment was repeated three times. 
##
p < 0.01, 
###
p < 
0.001, compared with sham. 
 
Fig. 7 Effects of antipsychotics on vesicular  [
3
H]dopamine transport in the presence of 
pargyline and ascorbic acid in PC12 cells. Pargyline (10 M) and ascorbic acid (1 mM) 
were added in order to inhibit dopamine metabolism and to prevent dopamine oxidation, 
respectively. Permeabilized PC12 cells were loaded with [
3
H]dopamine for 30 min in 
the presence of antipsychotics (10 M). Data shown are mean values ± S.E.M. (n=3) 
from a representative experiment. The experiment was repeated three times. 
#
p < 0.05, 
###
p < 0.001, compared with sham. 
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